The experimental medication helps people lose almost 25% of body weight

It has been shown that an experimental drug on weight loss helps people lose almost 25% of their body weight in 1A / 2B trials at an early stage.

The drug, Amycretine – developed by Novo Nordisk – works by reproducing two hunger hormones – Amylin, which regulates appetite and creates a feeling of fullness, and peptide 1 of the glucagon type (GLP -1), the same hormone which is used in ozempic and Wegovy to remove appetite and stimulate the secretion of insulin.

“Amycretin is the first treatment to exploit the two distinct biological pathways stimulated by Amylin and GLP-1 in a single molecule,” said Martin Holst Lange, executive vice-president and novo Nordisk development chief, in a press release sent to Fox News Digital.

The simple grandfather changes overthrew the pre-diabetes diagnosis which left it `petrified ”

In the study, which included 125 overweight or obese adults, participants who received weekly injections from Amycretine lost more weight than those who took a placebo, according to a press release from Novo Nordisk.

Those who obtained the highest doses (up to 60 mg) lost up to 24.3% of books after 36 weeks, compared to only 1.1% for the placebo group, according to the press release.

It has been shown that an experimental drug on weight loss helps people lose almost 25% of their body weight in 1A / 2B trials at an early stage. (istock)

A previous phase 1 trial of the oral version (pill) of AMYCritine also showed that the treatment was “safe and tolerable”, with an “observed reduction in body weight” compared to placebo, said the company.

Taking the pill once a day has resulted in about 10% weight loss, and those who doubled the dose lost 13%.

Your DNA could prevent you from losing weight, suggests a new study

Another advantage that researchers have underlined is that people taking Amycretin did not seem to strike a “weight loss platter”, continuing to lose book as long as they took it.

“The absence of a weight loss platform indicates the possibility of achieving additional weight reductions with prolonged treatment,” wrote Gasoirk, main specialist in clinical pharmacology of Novo Nordisk, in the results of the phase 1 study.

Novo Nordisk presented the latest discoveries at the American Diabetes Association in Chicago on June 22. ((Photo by Liselotte Sabroe / Scanpix Denmark / AFP via Getty Images)))

Novo Nordisk presented the latest discoveries at the American Diabetes Association in Chicago on June 22; They were also published in the Medical Review Lancet.

“We are satisfied with the promising results of Amycretine and the comments of the regulatory authorities and are delighted to advance the subcutaneous and oral versions of this molecule in phase 3 development for weight management,” said Martin Holst Lange, executive development vice-president in Novo Nordisk, in the press release.

“Amycretine is the first treatment to exploit the two distinct biological pathways stimulated by amyline and GLP-1 in a single molecule.”

“These results reflect our solid pipeline in obesity, (and) our focus on the progression of scientific innovation and the expansion of the range of options available for patients and health professionals.”

The most common side effects of Amycretine, similar to other GLP-1s, were the gastrointestinal symptoms-mainly nausea, vomiting and a decrease in appetite.

Click here to obtain the Fox News app

Adverse events were “light to moderate” in gravity, according to the researchers. More frequent doses have caused greater side effects.

It is important to closely monitor these side effects, advise experts, as gastrointestinal problems are common in obesity patients.

“Obesity is a chronic and multifactorial disease that requires a complete long -term approach,” said a doctor. (istock)

“Although the initial weight loss results are actually encouraging, other studies are necessary to ensure that the therapeutic benefits systematically prevail for potential risks, in particular with the long-term administration,” said Dr. Christine Ren-Fielding, director and head of bariatric surgery at Nyu Langone Weight Management, told Fox News Digital.

Click here to register for our Health Newsletter

While GLP -1 -based drugs – including this new experimental pill – can show promising results, Ren -Fielding, which has not been involved in the study, stressed that they “are not a remedy for obesity”.

“Obesity is a chronic and multifactorial disease that requires a complete and long-term approach,” she said at the time.

For more health items, visit www.foxnews.com/health

“Pharmacological treatments can play an important role in managing the condition, but they are often the most effective when combined with other interventions.”

Then, Novo Nordisk plans to prepare for phase 3 trials of the drug, in oral and injectable forms, for obesity management.